| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| Targets |
αvβ3 2.74 nM (IC50)
|
|---|---|
| ln Vitro |
In comparison to the PBS control group, HSDVHK dramatically reduced the bFGF-induced cell migration[1]. Since HSDVHK-NH2 (P11) is inactive for the complex formation of a denatured version of integrin–vitronectin, its recognition of the Arg-Gly-Asp (RGD)-binding site is site-specific. At an IC50 value of 25.72 nM, HSDVHK-NH2 (P11) exhibits substantial antagonistic activity against the avb3-GRGDSP interaction[2]. By inducing HUVEC cell death by caspase activations, HSDVHK-NH2 (P11) suppresses HUVEC proliferation. This mechanism is associated with enhanced p53 expression[3].
|
| Cell Assay |
Cell Proliferation Assay [3]
Cell Types: HUVEC cells. Tested Concentrations: 0.1, 1, 10, and 100 μg/mL. Incubation Duration: 72 h. Experimental Results: Dramatically inhibited HUVEC proliferation on denatured collagen-coated plates in a dose-dependent manner. |
| References |
[1]. Yoonsuk Lee, et al. High-throughput screening of novel peptide inhibitors of an integrin receptor from the hexapeptide library by using a protein microarray chip. J Biomol Screen. 2004 Dec;9(8):687-94.
[2]. Youngjin Choi, et al. Site-specific inhibition of integrin alpha v beta 3-vitronectin association by a ser-asp-val sequence through an Arg-Gly-Asp-binding site of the integrin. Proteomics. 2010 Jan;10(1):72-80. [3]. Ji-Young Bang, et al. Pharmacoproteomic analysis of a novel cell-permeable peptide inhibitor of tumor-induced angiogenesis. Mol Cell Proteomics. 2011 Aug;10(8):M110.005264. |
| Molecular Formula |
C30H48N12O9
|
|---|---|
| Molecular Weight |
720.78
|
| CAS # |
848644-86-0
|
| Related CAS # |
HSDVHK-NH2 TFA
|
| SMILES |
O=C([C@H](C(C)C)NC([C@H](CC(=O)O)NC([C@H](CO)NC([C@H](CC1=CN=CN1)N)=O)=O)=O)N[C@H](C(N[C@H](C(N)=O)CCCCN)=O)CC1=CN=CN1
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 250 mg/mL (346.85 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (138.74 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3874 mL | 6.9369 mL | 13.8739 mL | |
| 5 mM | 0.2775 mL | 1.3874 mL | 2.7748 mL | |
| 10 mM | 0.1387 mL | 0.6937 mL | 1.3874 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
